Cingulate SEC Filings

Welcome to our dedicated page for Cingulate SEC filings (Ticker: CINGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Cingulate Inc. (CINGW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Cingulate files a range of documents with the U.S. Securities and Exchange Commission that together outline its financial condition, capital structure, governance, and progress in developing its Precision Timed Release™ (PTR™) platform and lead ADHD candidate, CTx-1301.

Among the most relevant filings for CINGW are Form 10-Q quarterly reports and Form 10-K annual reports, which detail operating expenses such as research and development and general and administrative costs, net losses, cash and working capital levels, and accumulated deficit. These reports also discuss key milestones, including the submission and FDA acceptance of the New Drug Application (NDA) for CTx-1301 under the 505(b)(2) pathway and the assignment of a Prescription Drug User Fee Act (PDUFA) target action date.

Cingulate’s Form 8-K current reports are especially important for tracking material events. Recent 8-Ks describe unregistered sales of equity securities, executive and board changes, the submission of the CTx-1301 NDA, and the announcement of quarterly financial results via press release. Other filings, such as Form NT 10-Q, explain delays in periodic reports and reference management transitions, while the DEF 14A proxy statement for a special meeting outlines stockholder votes on equity issuance under a purchase agreement with Lincoln Park Capital.

For investors focused on the CINGW warrants and capital structure, filings like the Form S-1/A registration statement and related 8-Ks provide detail on committed equity facilities, warrant listings, and share issuances to lenders or service providers. On Stock Titan, these filings are updated in near real time from EDGAR, and AI-powered summaries help explain complex sections, such as equity financing terms, executive compensation arrangements, and risk disclosures, so users can more quickly interpret how each document may affect Cingulate’s development and financing plans.